Data from the pilot study demonstrated that Symphony has safely and reliably monitored blood glucose levels in the operating room and surgical intensive care unit at Tufts. There were no Symphony failures and no adverse events, indicating strong reliability of the Symphony for applications in the hospital critical care setting.
The pilot study was designed to evaluate the performance of Echo’s current generation Symphony system, including the use of its ultrasound-based skin permeation system and newly-improved biosensor technology incorporating proprietary hydrogel chemistry.
Stanley Nasraway, principal investigator of the study at Tufts, said: “These data serve as a strong signal that Symphony could advance the standard of care regarding tight glycemic control in the hospital critical care setting, much like continuous electrocardiographic monitoring and pulse oximetry changed standards of care in that setting.”